Prospectively randomized north central cancer treatment group trial of intensive-course fluorouracil combined with the l-isomer of intravenous leucovorin, oral leucovorin, or intravenous leucovorin for the treatment of advanced colorectal cancer

Journal of Clinical Oncology

Volumn 15, Issue 11, 1997, Pages 3320-3329

  Goldberg, Richard M ^a   Hatfield, Alan K ^a   Kahn, Michael ^a   Sargent, Daniel J ^a   Knost, James A ^a   O'Connell, Michael J ^a   Krook, James E ^a   Mailliard, James A ^a   Wiesenfeld, Martin ^a   Schaefer, Paul L ^a   Tirona, Maria Tria ^a   Moertel, Charles G ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DIARRHEA; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; THROMBOCYTOPENIA;

EID: 0030661574     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.11.3320     Document Type: Article

References (40)

1. Keyomarsi K, Moran RG: Folinic acid augmentation of the effects of fluoropyrimidines on murine and human leukemic cells. Cancer Res 46:5229-5235, 1986
2. Rustum YM, Trave F, Zakrzewski SF, et al: Biochemical and pharmacologic basis for potentiation of 5-fluorouracil action by leucovorin. NCI Monosr 5:165-170, 1987
3. Allegra CJ, Fine RL, Drake JC, et al: The effect of methotrexate on intracellular folate pools in human MCF-y breast cancer cells: Evidence for direct inhibition of purine synthesis. J Biol Chem 261:6478-6485, 1986
4. Houghton JA, Maroda SJ, Phillips JO, et al: Biochemical determinants of responsiveness to 5-fluorouracil and derivatives in xenografts of human colorectal adenocarcinoma in mice. Cancer Res 41-144-149, 1981
5. Evans RM, Laskin JD, Hakala MT: Effects of excess and deoxyinosine on the activity and site of action of 5-fluorouracil. Cancer Res 41:3288-3295, 1981
6. Erlichman C, Fine S, Wong A, et al: A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal cancer. J Clin Oncol 6:469-475, 1988
7. Petrelli N, Herrera L, Rustum Y, et al: A prospective randomized trial of 5-fluorouracil vs. 5-fluorouracil and high dose leucovorin + 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 5:1559-1565, 1987
8. Valone FH, Freidman MA, Wittlinger PS, et al: Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, hioh-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: A randomized trial of the Northern California Oncology Group. J Clin Oncol 7:1419-1426
9. Doroshaw JH, Bertrand M, Multhauf P, et al: Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J Clin Oncol 8:491-501, 1990
10. Petrelli N, Douglass HO, Herrera L, et al: The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial. J Clin Oncol 7:1419-1426, 1989
11. Poon MA, O'Connell MJ, Wieand HS, et al: Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 9:1967-1972, 1991
12. Anonymous: The Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 10:896-903, 1992
13. Sato JK, Newman EM, Moran RG: Preparation of (6R)-tetrahydrofolic acid and (6S)-5-formyltetrahydrofolic acid of high stereo chemical purity. Anal Biochem 154:516-524, 1986
14. Sirotnak FM, Chello PL, Moccio DM, et al: Stereo specificity at carbon 6 of formyl tetrahydrofolate as a competitive inhibitor of transport and cytotoxicity of methotrexate in vitro. Biochem Pharmacol 28:2993-2997, 1979
15. Jolivet J, Bertrand R: Lack of interference by the unnatural isomer of 5-formyltetrahydrofolate with the effects of the natural isomer in leucovorin preparations. J Natl Cancer Inst 81:1175-1178, 1989
16. Straw JA, Szapary D, Wynn WT: Pharmacokinetics of the diastereo isomers of leucovorin after intravenous and oral administration in normal subjects. Cancer Res 44:3114-3119, 1984
17. Wainer IM, Stiffin RM: Direct resolution of the stereo isomers of leucovorin and 5-methyltetrahydrofolate using a bovine serum albumen high performance liquid chromotographic chiral stationary phase coupled to a achiral phenyl column. J Chromotogr 424:158-162, 1988
18. White JC, Bailey BD, Goldman ID: Lack of stereospecificity at carbon 6 of methyltetrahydrofolate transport in Erlich ascites tumor cells: Carrier mediated transport of both stereoisomers. J Biol Chem 253:242-245, 1978
19. Houghton JA, Williams LG, DeGraff SS, et al: Selectivity of CF and 5-fluorouracil: Critical role of polyglutamylation. Adv Exp Med Biol 244:85-95, 1988
20. Romanin IA, Lin JT, Niedzwieck ID, et al: Role of polyglutamates in biochemical modulation of fluoropyrimidines by leucovorin. Cancer Res 51:789-793, 1991
21. McGuire BW, Sai LL, Haynes JD, et al: Absorption kinetics of orally administered leucovorin calcium. NCI Monogr 5:47-56, 1987
22. Radvadpa RS, Houghton PJ, Houghton JA: Effect of polyglutamation of 5,10-methylenetetrahydrofolate on the binding of 5-fluoro-2′-deoxyuridylate to thymidylate synthase purified from a human colon adenocarcinoma xenograft. Biochem Pharmacol 38:335-342, 1989
23. Schilsky RL, Choi KE, Vokes EE, et al: Clinical pharmacology of the stereo isomers of leucovorin during repeated oral dosing. Cancer 63:1018-1021, 1989
24. Machover D, Goldschmidt E, Chollet P, et al: Treatment of advanced colorectal and gastric carcinomas with 5-FU and high dose folinic acid. J Clin Oncol 4:685-696, 1986
25. Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometric 31:103-115, 1975
26. Mahood DJ, Dose AM, Loprinzi CL, et al: Inhibition of fluorouracil-induced stomatitis by oral cryotherapy. J Clin Oncol 9:449-452, 1991
27. Cox DR: Regression models and life-tables. J R Stat Soc (B) 34:187-220, 1972
28. Becker R, Chambers J, Wilks A: The New S Language. Pacific Grove, CA, Wadsworth & Brooks/Cole, 1988
29. Kaplan EL, Meir P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
30. Mantel N, Haenszel W: Statistical Aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748, 1959
31. Buroker TR, O'Connell MJ, Wieand HS, et al: Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 12:14-20, 1994
32. Poon MA, O'Connell MJ, Moertel CG, et al: Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in advanced colorectal carcinoma. J Clin Oncol 7:1407-1418, 1989
33. Hines JD, Zakem MH, Adelstein DJ, et al: Unavailability of high dose oral leucovorin after intravenous and oral administration to normal subjects. Cancer Res 44:3114-3119, 1984
34. Hines JD, Adelstein DJ, Spiess JL, et al: Efficacy of high dose oral leucovorin and 5-fluorouracil in advanced colorectal carcinoma: Plasma and tissue pharmacokinetics. Cancer 63:1022-1025, 1989
35. Machover D, Grison X, Goldschmidt E, et al: 5-Fluorouracil combined with the pure [6S]-stereoisomer of folinic acid in high doses for the treatment of patients with advanced colorectal carcinoma: A phase I-II study of two consecutive regimens. Adv Exp Med Biol 339:81-98, 1993
36. Meropol N, Petrelli NJ, Rustum YM, et al: A phase II and pharmacokinetic study of 6S-leucovorin plus 5-fluorouracil in patients with colorectal carcinoma. Invest New Drugs 13:149-155, 1995
37. Schuller J, Czejka M, Pietrzak C, et al: Serum and tissue levels of 1-folinic acid acid (fa) after iv bolus of either racemic (d,1) or pure 1-enantiomer(1-fa). Proc Am Soc Clin Oncol 15:175, 1996 (abstr)
38. Erlichman C, Fine S, Kerr I, et al: A phase II trial of 5-fluorouracil and 1-leucovorin in patients with metastatic colorectal cancer. Am J Clin Oncol 19:26-31, 1996
39. Konoshi K, Yabushita K, Taguchi T, et al: A phase II trial of 1-leucovorin and 5-fluorouracil in advanced colorectal cancer: 1-leucovorin and 5-fu study group. Jpn J Cancer Chemother 22:925-932, 1995
40. Scheithauer W, Kornek G, Marczell A, et al: Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure 1-isomer of leucovorin for the treatment of advanced colorectal cancer: A randomized phase III study. J Clin Oncol 15:908-914, 1997